completed research text box

Halatsch Headshot

Principal Investigator: Dr. Marc-Eric Halatsch

Research Institution: Ulm University 

Disease: Glioblastoma 

Research Description: For decades, new experimental therapies have repeatedly failed to improve the outcome of patients relapsing after initial treatment of the brain cancer glioblastoma. The chemotherapy drug temozolomide is used for the initial treatment of these brain cancers. Dr. Halatsch and his team surveyed the research literature looking for approved non-cancer drugs that inhibit key cellular pathways in glioblastoma. Using selection criteria including low likelihood of increasing patient side effects, good quality of life maintenance and adequate clinical experience with the drug, they identified nine repurposed drugs. These drugs will be given together in combinations with low-dose, uninterrupted, daily temozolomide. The primary objective is to assess the safety and tolerability of the combination treatment in patients with recurrent glioblastoma. The secondary objectives are to evaluate overall survival, progression-free survival after six months and best tumor response.

CWR funding role: Participating funder

Completed: 2020

Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*


If the link above doesn't work, please contact our Admin support at with your Full Name and Email Address to sign up!


Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.


Sunday the 27th. Copyright 2018 Cures Within Reach.